Literature DB >> 8569175

Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations.

S R Lakhani1, D N Slack, R A Hamoudi, N Collins, M R Stratton, J P Sloane.   

Abstract

Previously, we developed methodology for studying allelic imbalance (AI) in preinvasive breast disease and showed that AI identified at various chromosomal loci in invasive carcinoma is already present in in situ carcinoma and atypical hyperplasia. We now extend this work by looking for Ai in hyperplasia of usual type (HUT), apocrine cysts (AC), and papilloma (Pap) of the breast. HUT, AC, and Pap were identified in formalin-fixed, paraffin-embedded sections of benign breast biopsies and isolated using a microdissection technique. AI was investigated using polymorphic microsatellite markers and PCR. AI was identified in 3/23 (13%) informative cases of HUT at 17q (D17S250), 2/43 (4.7%) at 17p (D17S796), 1/22 (4.5%) at 16q (D16S413), and 0/18 (0%) at 13q (D13S267). No particular histologic feature of HUT predicted the presence of AI. No examples of AC or Pap exhibited AI at any of the markers studied. AI previously identified at various chromosomal loci in invasive carcinoma, in situ carcinoma, and atypical hyperplasia is present at low frequency in HUT in benign breast biopsies but not in AC or Pap. The possibility that AI in the latter could be masked by contamination from stromal and myoepithelial cells cannot, however, be excluded at this stage. At least a proportion of HUT thus appear to be clonal (neoplastic) rather than hyperplastic proliferations as their name suggests. The significance of AI in the pathogenesis of HUT or its subsequent progression to carcinoma is not yet clear and requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8569175

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  28 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Estrogen receptor-positive proliferating cells in the normal and precancerous breast.

Authors:  B S Shoker; C Jarvis; R B Clarke; E Anderson; J Hewlett; M P Davies; D R Sibson; J P Sloane
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  [Anatomy of the breast].

Authors:  W Böcker; D Hungermann; T Decker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

4.  Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization.

Authors:  Yuxia Gao; Yun Niu; Xiaowei Wang; Li Wei; Song Lu
Journal:  J Mol Med (Berl)       Date:  2008-10-21       Impact factor: 4.599

Review 5.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis.

Authors:  Jane E Visvader
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

Review 6.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 7.  Isolation and characterization of human mammary stem cells.

Authors:  R B Clarke
Journal:  Cell Prolif       Date:  2005-12       Impact factor: 6.831

8.  [The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis].

Authors:  H Bürger; C Kersting; D Hungermann; T Decker; W Böcker
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

9.  Genetically abnormal clones in histologically normal breast tissue.

Authors:  P S Larson; A de las Morenas; L A Cupples; K Huang; C L Rosenberg
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468.

Authors:  Konstantin Agelopoulos; Burkhard Greve; Hartmut Schmidt; Heike Pospisil; Stefan Kurtz; Kai Bartkowiak; Antje Andreas; Marek Wieczorek; Eberhard Korsching; Horst Buerger; Burkhard Brandt
Journal:  BMC Cancer       Date:  2010-03-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.